| Comirnaty LP.8.1 30 Mikrogramm, Injektionsdispersion in einer Fertigspritze - | | 70403001 | | Pfizer AG | | Comirnaty LP.8.1 30 Mikrogramm, Injektionsdispersion in einer Fertigspritze | | 06.08.2025 | | Generikum | | 06.08.2025 | | Covid-19, Rna-Based Vaccine (J07BN01) | | | | WHO-DDD | | 05.08.2030 | | 80000. | | | | 08.08. | | | | | | | | Nein | | | | FI | | PI | | 68.36 | | | | 10% | | 89.90 | | FB | | | | 7680704030010 | | Impfstoffe | | | | |
| | Zusammensetzung | | Suspension: COVID-19 mRNA LP.8.1 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-N,N-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. | | Packungsbestandteile | | | | Quelle | | | |
|
|
